Biotest Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Peter Janssen

Algemeen directeur

€926.0k

Totale compensatie

Percentage CEO-salaris	47.5%
Dienstverband CEO	2.2yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	2.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Peter Janssen's beloning veranderd ten opzichte van Biotest's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	€69m
Jun 30 2024	n/a	n/a	€164m
Mar 31 2024	n/a	n/a	€177m
Dec 31 2023	€926k	€440k	€127m
Sep 30 2023	n/a	n/a	€91m
Jun 30 2023	n/a	n/a	-€10m
Mar 31 2023	n/a	n/a	-€47m
Dec 31 2022	€333k	€147k	-€32m

Compensatie versus markt: De totale vergoeding ($USD 964.38K ) Peter } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 2.14M ).

Compensatie versus inkomsten: De beloning van Peter is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Peter Janssen (56 yo)

2.2yrs

Tenure

€926,000

Compensatie

Mr. Peter Janssen serves as Member of Management Board for Biotest Aktiengesellschaft since September 1, 2022 and served as its Chief Operating Officer since September 2022 until January 2024. He has been...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Janssen	CEO & Chairman of the Board of Management	2.2yrs	€926.00k	geen gegevens
Dirk Schuck	Member of Supervisory Board	2.8yrs	€44.00k	geen gegevens
Monika Buttkereit	Head of Investor Relations	no data	geen gegevens	geen gegevens
Christina Erb	Head of Corporate HR	9.3yrs	geen gegevens	geen gegevens
Martin Möller	Group Finance and Treasury	no data	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van 0N6Z wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Dirk Schuck	Member of Supervisory Board	2.5yrs	€44.00k	geen gegevens
Raimon Grifols Roura	Member of Supervisory Board	1.5yrs	€29.00k	geen gegevens
Bernhard R. Ehmer	Chairman of the Supervisory Board	2.5yrs	€132.00k	geen gegevens
David Bell	Member of Supervisory Board	2.4yrs	€44.00k	geen gegevens
Jurgen Heilmann	Employee Representative Member of Supervisory Board	13.2yrs	€44.00k	geen gegevens

2.5yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0N6Z wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.5 jaar), wat duidt op een nieuw bestuur.

Biotest Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024

Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024

Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023

Biotest AG Announces Board Changes

Recent updates

Biotest Aktiengesellschaft to Report Fiscal Year 2024 Results on Mar 28, 2025

Biotest Aktiengesellschaft to Report Q2, 2024 Results on Aug 06, 2024

Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies

Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024

Biotest Aktiengesellschaft to Report First Half, 2024 Results on Jul 30, 2024

Biotest Aktiengesellschaft to Report Fiscal Year 2023 Results on Mar 28, 2024

Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023

Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024

Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with Trimodulin

Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin Yimmugo

Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023

Biotest Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 23, 2023

Biotest AG Conducts Clinical Phase III Study PreCyssion with Cmv Hyperimmunoglobulin (Cytotect CP Biotest-) for the Prevention of CMV Infection in the Unborn Child in Germany

Biotest AG Achieves Important Milestone in Phase III Study in Acquired Fibrinogen Deficiency

Biotest AG Announces Board Changes

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Biotest Submits Marketing Authorisation Application for IgG Next Generation

Biotest AG Announces Biotest Treats First CMV-Positive Pregnant Woman in Phase III Clinical Trial to Prevent Transmission of CMV Infection to the Unborn Child

Biotest AG Accelerates Trimodulin Development in Hospitalized Covid-19 Patients with Federal Funding from the German Ministries of Health, and Education & Research

Biotest Receives Approval for Phase III Clinical Trial in Pregnant Women for Prevention of CMV Infection of the Unborn Baby

Biotest Announces the Outcome for Its ESsCOVID (Escape from Severe COVID-19) Trial in Patients with Severe COVID-19

Biotest AG Provides Earnings Guidance for the Year 2021

Biotest AG Successfully Completes Recruitment for Its Clinical Trial with Trimodulin in Severe Covid-19 Patients

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd